Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Expert Perspective

Posted: Tuesday, March 5, 2019

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute, discusses what makes the combination of immune checkpoint inhibitors and PARP inhibitors so appealing in the treatment of BRCA-mutation carriers.